3-Month post-operative increase in FGF21 is predictive of one-year weight loss after bariatric surgery
Abstract
Purpose The association between bariatric surgery outcome and blood levels of fibroblast growth factor 21 (FGF21) remains controversial. Many patients displayed stable or decreased FGF21 one year after bariatric surgery. Nevertheless, there is often an early increase FGF21 concentration in the post-surgery period. The aim of this study was to investigate the relationship between 3-month FGF21 response and percentage total weight loss at one year after bariatric surgery.Materials and methods In this prospective monocentric study, a total of 144 patients with obesity grade 2-3 were included; 61% of them underwent a sleeve gastrectomy and 39% a Roux-en-Y gastric bypass. Data analysis was carried out to determine the relation between 3-month plasma FGF21 response and weight loss one year after bariatric surgery. Multiple adjustments were done including degree of weight loss after 3 months.Results FGF21 significantly increased between baseline and Month 3 (n = 144, p < 10-3), then decreased between Month 3 and Month 6 (n = 142, p = 0.047) and was not different from baseline at Month 12 (n = 142, p = 0.86). The 3-month-FGF21 response adjusted to body weight loss was not different between types of bariatric surgery. The 3-month-FGF21 response was associated to body weight loss at Month 6 (r = -0.19, p = 0.02) and Month 12 (r = -0.34, p < 10-4). After multiple regression analysis, only Month 12 body weight loss remained associated to 3-month FGF21 response (r = -0.3, p = 0.02).Conclusion This study showed that the magnitude of changes in FGF21 at 3 months after bariatric surgery emerged as an independent predictor of one-year body weight loss irrespective of the type of surgery.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies have reported transitory increases in circulating FGF-21 following bariatric surgery and GLP-1 receptor agonist treatment.
“Although some studies have reported transitory increases in circulating FGF-21 following bariatric surgery 33 and glucagon-like peptide-1 receptor agonist treatment, 34”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [33]
Cites
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · see citing works
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · see citing works
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607 · see citing works
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512 · see citing works
Di Lorenzo, N., Antoniou, S. A., Batterham, R. L., Busetto, L., Godoroja, D., Iossa, A., Carrano, F. M., Agresta, F., Alarçon, I., Azran, C., et al. (2020) · Surgical Endoscopy · doi:10.1007/s00464-020-07555-y · Cited by 465 · see citing works
Mardinoğlu, A., Wu, H., Björnson, E., Zhang, C., Hakkarainen, A., Räsänen, S., Lee, S., Mancina, R. M., Bergentall, M., Pietiläinen, K. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.005 · Cited by 455 · see citing works
Flippo, K. H., & Potthoff, M. J. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00354-2 · Cited by 311 · see citing works
FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans
Søberg, S., Sandholt, C. H., Jespersen, N. Z., Toft, U., Madsen, A. L., von Holstein-Rathlou, S., Grevengoed, T. J., Christensen, K. B., Bredie, W. L. P., Potthoff, M. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.009 · Cited by 216 · see citing works
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 209 · see citing works
Wölnerhanssen, B. K., Peterli, R., Steinert, R. E., Peters, T. T. A., Borbély, Y., & Beglinger, C. (2011) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2011.01.044 · Cited by 206 · see citing works
Gómez‐Ambrosi, J., Gallego-Escuredo, J. M., Catalán, V., Rodrı́guez, A., Domingo, P., Moncada, R., Valentí, V., Salvador, J., Giralt, M., Villarroya, F., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.04.027 · Cited by 168 · see citing works
Going Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 164 · see citing works
Haluzíková, D., Lacinová, Z., Kaválková, P., Drápalová, J., Křížová, J., Bártlová, M., Mráz, M., Petr, T., Vı́tek, L., Kasalicky, M., et al. (2013) · Obesity · doi:10.1002/oby.20208 · Cited by 118 · see citing works
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J., Sharp, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.070 · Cited by 101 · see citing works
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
Zarei, M., Pizarro‐Delgado, J., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.005 · Cited by 92 · see citing works
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 87 · see citing works
Crujeiras, A. B., Gómez-Arbeláez, D., Zulet, M. Á., Carreira, M. C., Sajoux, I., de Luis, D. A., Castro, A. I., Baltar, J., de la Torre, I. B., Sueiro, A. M., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.138 · Cited by 82 · see citing works
Serum FGF-21 Levels in Type 2 Diabetic Patients
Cheng, X., Zhu, B. L., Jiang, F., & Fan, H. (2011) · Endocrine Research · doi:10.3109/07435800.2011.558550 · Cited by 73 · see citing works
Lips, M. A., de Groot, G. H., Berends, F. J., Wiezer, M. J., van Wagensveld, B. A., Swank, D. J., Luijten, A. A. P. M., van Dijk, K. W., Pijl, H., Jansen, P. L. M., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12496 · Cited by 65 · see citing works
Woo, Y. C., Lee, C., Fong, C. H.-Y., Xu, A., Tso, A. W. K., Cheung, B. M. Y., & Lam, K. S. L. (2016) · Clinical Endocrinology · doi:10.1111/cen.13229 · Cited by 55 · see citing works
Metabolomic signatures after bariatric surgery – a systematic review
Vaz, M. E. D. L., Pereira, S. S., & Monteiro, M. P. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09695-5 · Cited by 49 · see citing works
Fibroblast growth factor 21: an endocrine inhibitor of sugar and alcohol appetite
von Holstein‐Rathlou, S., & Gillum, M. P. (2019) · The Journal of Physiology · doi:10.1113/jp277117 · Cited by 44 · see citing works
Metabolic adaptations after bariatric surgery: Adipokines, myokines and hepatokines
Faramia, J., Ostinelli, G., Drolet-Labelle, V., Picard, F., & Tchernof, A. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.06.005 · Cited by 44 · see citing works
Roux-en-Y Gastric Bypass Surgery Has Unique Effects on Postprandial FGF21 but Not FGF19 Secretion
Harris, L.-A. L. S., Smith, G. I., Mittendorfer, B., Eagon, J. C., Okunade, A. L., Patterson, B. W., & Klein, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01295 · Cited by 31 · see citing works
Strączkowski, M., Karczewska‐Kupczewska, M., Adamska, A., Otziomek, E., Kowalska, I., & Nikołajuk, A. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.10 · Cited by 25 · see citing works
Hosseinzadeh, A., Roever, L., & Alizadeh, S. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04807-7 · Cited by 22 · see citing works
Guo, J., Chen, H.-H., Lee, W., Chen, S., Lee, S., & Chen, C. (2022) · Nutrients · doi:10.3390/nu14030645 · Cited by 20 · see citing works
Effect of bariatric surgery on circulating FGF‐19: A systematic review and meta‐analysis
Ryan, P. M., Hayward, N. E., Sless, R. T., Garwood, P., & Rahmani, J. (2020) · Obesity Reviews · doi:10.1111/obr.13038 · Cited by 19 · see citing works
Xiao, F., Shi, X., Huang, P., Zeng, X., Wang, L., Zeng, J., Liu, C., Yan, B., Song, H., Xu, Y., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101221 · Cited by 18 · see citing works
Hany, M., Demerdash, H. M., Zidan, A., Agayby, A. S. S., & Torensma, B. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06384-3 · Cited by 14 · see citing works
Expression of fibroblast growth factor 21 in patients with biliary atresia
Li, D., Lu, T., Shen, C., Liu, Y., Zhang, J., Shan, Y., Luo, Y., Xi, Z., Qiu, B., Chen, Q., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.03.003 · Cited by 11 · see citing works
Poloczek, J., Kazura, W., Kwaśnicka, E., Gumprecht, J., Jochem, J., & Stygar, D. M. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5527107 · Cited by 10 · see citing works
Nielsen, M. S., Ritz, C., Chenchar, A., Bredie, W. L. P., Gillum, M. P., & Sjödin, A. M. (2021) · Nutrients · doi:10.3390/nu13113840 · Cited by 7 · see citing works
Fink‐Miller, E. L., & Rigby, A. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2385-8 · Cited by 5 · see citing works
Nielsen, M. S., Søberg, S., Schmidt, J. B., Chenchar, A., Sjödin, A. M., & Gillum, M. P. (2021) · PeerJ · doi:10.7717/peerj.11174 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide
Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.04.044 · Cited by 5 · see citing works
- Authors
- De Luca, A., Delaye, J.-B., Fauchier, G., Bourbao-Tournois, C., Champion, H., Bourdon, G., Dupont, J., Froment, P., Dufour, D., & Ducluzeau, P.-H.
- Affiliations
- Centre Hospitalier Universitaire de Tours (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- ORCID
- Venue
- Obesity Surgery
- Published
- 2023-06-30
- Volume
- 33
- Issue
- 8
- Pages
- 2468-2474
- ISSN
- 0960-8923 (ISSN-L)
- 1708-0428
- OpenAlex
- W4382654258
- Cited by
- 11
- References
- 36
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Obesity Surgery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Rheumatology › GDF15 and Related Biomarkers
- Keywords
- FGF21, bariatric surgery
- MeSH terms
- Fibroblast Growth Factors, Gastrectomy, Humans, Obesity, Obesity, Morbid, Prospective Studies, Retrospective Studies, Gastric Bypass, Weight Loss, Treatment Outcome, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
